David Herman

Mr. David Herman

École des Hautes Études en Santé Publique, Rennes, Bretagne, France
orcid
Epidemiologist and Biostatistician

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
ETEric P. Twomey
Eric P. Twomey
David HermanDavid Herman
David Herman
JMJosé Antonio Marín-Rodríguez
José Antonio Marín-Rodríguez
JJJose J. Jimenez-Moleon
Jose J. Jimenez-Moleon
Background: Vaccination against influenza has proven to reduce influenza-caused hospital entries, treatment times in intensive care units and hospitalisation costs for treating people with Diabetes Mellitus (DM). Despite the existing influenza vaccination recommendations for all persons with DM, in Spain, vaccination hesitancy remains substantial, and vaccination rates lag behind target. We aimed to assess predictors for influenza vaccination uptake and reasons for non-adherence among individuals with DM. Methods: Data from the 2020 European Health Interview Survey were analysed using uni- and multivariable logistic regression models, stratified by age group and including possible confounders and vaccination as an outcome. Associations with the sociodemographic profile, healthcare access and substance use were explored. Results: Our analysis included 2194 individuals with DM over the age of 15, showing an influenza vaccination rate of 53%. The findings revealed significant predictors of vaccination uptake, including age over 60 years and robust social support. Conversely, younger age, higher education levels, infrequent healthcare interactions and economic barriers emerged as significant obstacles to vaccination. Conclusions: To enhance vaccination rates, targeted public health interventions should emphasise the importance of vaccination for younger, more educated individuals with DM, those facing economic barriers and those with lower levels of social support, which could bridge the existing gap in vaccination coverage.

11 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Eric Phillip TwomeyEric Phillip Twomey
Eric Phillip Twomey
David HermanDavid Herman
David Herman
JMJosé Antonio Marín-Rodríguez
José Antonio Marín-Rodríguez
JJJose J. Jimenez-Moleon
Jose J. Jimenez-Moleon
Background: Vaccination against influenza has proven to reduce influenza-caused hospital entries, treatment times in intensive care units and hospitalisation costs for treating people with Diabetes Mellitus. Despite the existing influenza vaccination recommendations for all persons with Diabetes Mellitus, in Spain, vaccination rates lag behind target. We aimed to assess predictors for vaccination uptake and reasons for non-adherence. Methods: Data from the 2020 European Health Interview Survey were analysed using uni-and multivariable logistic regression models, stratified by age group and including possible confounders and vaccination as an outcome. Associations to the sociodemographic profile, healthcare access and substance use were explored. Results: Our analysis included 2,194 individuals with Diabetes Mellitus over the age of 15, showing an influenza vaccination rate of 53%. The findings revealed significant predictors of vaccination uptake, including age over 60 years and robust social support. Conversely, younger age, higher education levels, infrequent healthcare interactions, and economic barriers emerged as significant obstacles to vaccination. Conclusions: To enhance vaccination rates, targeted public health interventions should emphasize the importance of vaccination for younger, more educated individuals with DM, those facing economic barriers, and those with lower levels of social support could bridge the existing gap in vaccination coverage.

3 June 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TMTamara Mangiaterra
Tamara Mangiaterra
RARuth Alonso-Alonso
Ruth Alonso-Alonso
ARAndrés Rabinovich
Andrés Rabinovich
David HermanDavid Herman
David Herman
MSMarcela De Dios Soler
Marcela De Dios Soler
PCPaola Chabay
Paola Chabay
Diffuse large B-cell lymphoma (DLBCL) is a neoplasm affecting adults and children, with different clinical behaviors between age groups. To shed light on those differences, gene expression profiling was evaluated in 48 formalin-fixed paraffin-embedded biopsies of patients with DLBCL. Sixteen differentially expressed genes in pediatric DLBCL compared to adults were demonstrated, involving lymphocyte differentiation, oncogenic signaling and chemotaxis. Pathway analysis confirmed the enrichment in proliferation-related pathways. In addition, the increased presence of NKCD56dim cells in pediatric patients suggests a cytotoxic immune response in this group, perhaps explaining their better outcome. Exclusion of Epstein Barr virus (EBV) + DLBCL, NOS, showed, in pediatric cases, additional downregulated genes associated with immune regulators and checkpoint genes. This suggested EBV infection may have on the modulation of immune response in pediatric lymphomas. Survival analysis showed associations between genes such as MYC, NT5E and CD34, and event-free survival in pediatric patients. Furthermore, higher expression of MYC in children displayed higher risk of death or relapse, while lower expression of NT5E and CD34 was associated with lower risk. This study identifies distinct immune response and proliferation gene expression patterns in pediatric DLBCL compared to adults, and the interaction with tumor microenvironment, with potential implications for disease pathogenesis.

3 May 2025 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
David HermanDavid Herman
David Herman
JTJulien Tanniou
Julien Tanniou
ELEmmanuelle Leray
Emmanuelle Leray
CPChloe Pierret
Chloe Pierret
QPQuentin Pilard
Quentin Pilard